CTRI/2017/08/009565尚未招募2 期
A Phase II randomized controlled trial elucidating the gene expression profile using transcriptomic analysis in children with autosomal recessive congenital ichthyosis treated with vitamin D and acitretin.
Department of Science Technology0 个研究点目标入组 20 人开始时间: 待定最近更新:
试验速览
- 阶段
- 2 期
- 状态
- 尚未招募
- 发起方
- 入组人数
- 20
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
入选标准
- •1.All patients of autosomal recessive congenital ichthyosis belonging to either lamellar or congenital ichthyosiform erythroderma phenotypes.
- •Lamellar Ichthyosis:
- •a. Children with large parchment like scales all over the body
- •b. Scales are larger, severely thicker and brownish that might fracture resulting in tessellated or tile like pattern.
- •c. Hyperkeratotic and more verrucous scaling around the joints
- •d. Erythroderma
- •e. Severe ectropion
- •Congenital Ichthyosiform erythroderma
- •f. Prominent erythroderma
- •g. Scaling is present all over the body, less severe than seen in lamellar phenotype.
- •h. Scales are lighter and thinner
- •2.Serum 25 (OH) D levels < 20 ng/mL with or without rickets
- •3.Age > 6 months
排除标准
- •1.Other variants of congenital Ichthyosis (Ichthyosis vulgaris, X linked recessive ichthyosis, epidermolytic ichthyosis)
- •2.Children with liver and kidney impairment or any other systemic illness.
研究者
相似试验
暂停
2 期
A phase II randomized clinical trial to determine the effectiveness of goreisan and saireito for lower limb lymphedema in women treated for gynecologic cancerower Limb LymphedemaLymphedemaD008209JPRN-jRCT1041190019Kajiyama Hiroaki40
进行中（未招募）
1 期
A study, in which patients with late stage lung cancer and changes in a gene called EGFR, will be first treated for 8 weeks with the drug erlotinib and if they have clinical benfit will receive either a combination of an experimental drug called LY2875358 plus erlotinib or erlotinib alone.on-Small Cell Lung CancerMedDRA version: 20.0 Level: PT Classification code 10059515 Term: Non-small cell lung cancer metastatic System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2012-005476-33-FREli Lilly and Company150
进行中（未招募）
1 期
A study, in which patients with late stage lung cancer and changes in a gene called EGFR, will be first treated for 8 weeks with the drug erlotinib and if they have clinical benfit will receive either a combination of an experimental drug called LY2875358 plus erlotinib or erlotinib alone.on-Small Cell Lung CancerMedDRA version: 14.1Level: PTClassification code 10059515Term: Non-small cell lung cancer metastaticSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2012-005476-33-ITEli Lilly and Company150
进行中（未招募）
1 期
A study, in which patients with late stage lung cancer and changes in a gene called EGFR, will be first treated for 8 weeks with the drug erlotinib and if they have clinical benfit will receive either a combination of an experimental drug called LY2875358 plus erlotinib or erlotinib alone.on-Small Cell Lung CancerMedDRA version: 17.1Level: PTClassification code 10059515Term: Non-small cell lung cancer metastaticSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2012-005476-33-DKEli Lilly and Company179
进行中（未招募）
不适用
A study, in which patients with late stage lung cancer and changes in a gene called EGFR, will be first treated for 8 weeks with the drug erlotinib and if they have clinical benfit will receive either a combination of an experimental drug called LY2875358 plus erlotinib or erlotinib alone.on-Small Cell Lung CancerMedDRA version: 17.1Level: PTClassification code 10059515Term: Non-small cell lung cancer metastaticSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2012-005476-33-NLEli Lilly and Company179